Form 4: Arbutus Biopharma's Interim CEO Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Michael J. McElhaugh, Interim President & CEO of Arbutus Biopharma, was granted stock options and restricted stock units on February 14, 2025.
Summary
- Michael J. McElhaugh, the Interim President & CEO of Arbutus Biopharma Corp, received stock options and restricted stock units (RSUs) on February 14, 2025.
- He was granted 177,000 RSUs, each representing a contingent right to receive one common share.
- These RSUs vest in three equal annual installments starting one year from the grant date, contingent upon his continued service.
- He also received options to purchase 718,800 common shares at an exercise price of $3.29 per share.
- These options vest over a four-year period, with 1/48th of the shares vesting monthly from one month after the grant date, also subject to continuous service.
- Following these transactions, McElhaugh beneficially owns 1,658,003 common shares and options for 718,800 shares.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which are generally viewed neutrally to positively as they align management interests with shareholders. The vesting schedules suggest a long-term commitment from the executive.
Positives
- The grant of RSUs and stock options aligns the Interim CEO's interests with those of the shareholders.
- The vesting schedules for both RSUs and stock options incentivize continued service and performance.
Industry Context
Grants of stock options and restricted stock units are common practices in the biopharmaceutical industry to incentivize executives and align their interests with those of shareholders. The vesting schedules are designed to retain key personnel and encourage long-term value creation.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices in the biotech industry.
- Vesting schedules of 3-4 years are typical for these types of equity grants.
- Companies like Gilead Sciences, Amgen, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
- Employees may see the grants as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the grant of restricted stock units and stock options. |
| 02/14/2035 | Expiration date of the stock options. |
| 02/19/2025 | Date of signature on the Form 4 filing. |
Keywords
Arbutus Biopharma, Michael J. McElhaugh, Interim CEO, Stock Options, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, ABUS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.